PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19926732-7	2010	Budesonide inhibited release of all three cytokines (EC(50) TNF-alpha: 1.2+/-0.4 nM; GM-CSF: 0.4+/-0.2 nM; CXCL8: 0.4+/-0.1 nM; n = 3-4).	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	85-91	
15654514-1	2004	OBJECTIVE: To determine the inhibitory potency of budesonide on interleukin (IL)-4, 6 and 8, GM-CSF and TNF-alpha release from the human mast cell line (HMC-1) in comparison with the systemic glucocorticosteroid, dexamethasone, and H(1) antagonist, desloratadine.	Budesonide	50-60	colony stimulating factor 2	Homo sapiens	93-99	
12418591-8	2002	A concentration of 1 nM budesonide inhibited GM-CSF production by more than 50% at all time points.	Budesonide	24-34	colony stimulating factor 2	Homo sapiens	45-51	
11867828-6	2002	RESULTS: Formoterol exerted an additive effect on the inhibition of IL-1beta stimulated ICAM-1 and VCAM-1 upregulation and GM-CSF production by budesonide in concentrations of 10(-9) M and above (p<0.05).	Budesonide	144-154	colony stimulating factor 2	Homo sapiens	123-129	
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	colony stimulating factor 2	Homo sapiens	124-172	
11587995-5	2001	After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium.	Budesonide	6-16	colony stimulating factor 2	Homo sapiens	174-180	
11491146-4	2001	Budesonide (10(-8) M) reduced the amounts of both cytokines (GM-CSF and IL-8) by 40%.	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	61-67	
11491146-0	2001	Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells.	Budesonide	26-36	colony stimulating factor 2	Homo sapiens	40-46	
11491146-5	2001	Simultaneous addition of formoterol and budesonide reduced GM-CSF levels approximately 75%, while IL-8 levels were decreased approximately 40%, similar to the reduction obtained with budesonide alone.	Budesonide	40-50	colony stimulating factor 2	Homo sapiens	59-65	
11491146-9	2001	In conclusion, the combination of budesonide and formoterol reduces the secretion of granulocyte macrophage-colony stimulating factor to basal levels and counteracts the capacity of formoterol alone to induce interleukin-8 production, modulations which may facilitate improved asthma control.	Budesonide	34-44	colony stimulating factor 2	Homo sapiens	85-133	
9811532-10	1998	The maximal inhibitory effect of budesonide was seen at 10(-8) M. The inhibition of IL-12 production was significantly higher than the inhibition of GM-CSF (P<0.01) or IL-1beta (P<0.001).	Budesonide	33-43	colony stimulating factor 2	Homo sapiens	149-155	
11112128-6	2000	Budesonide attenuated the allergen-induced increase in circulating eosinophils (4.0 +/- 0.4 x 10(5)/ml versus 6.5 +/- 0.7 x 10(5)/ml, p = 0.0001), circulating Eo/B CFU (12.4 +/- 2.3/10(6) NAMC versus 18.8 +/- 4.6/10(6) NAMC, p = 0.05), and immunolocalization of GM-CSF in Eo/B colony cells (11.8 +/- 1.9% positive versus 18.0 +/- 2.2%, p = 0.01) but not immunolocalization of IL-5 (7.9 +/- 1.4% versus 4.5 +/- 0.6%, p > 0.05).	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	262-268	
11112128-7	2000	Inhaled budesonide attenuated the number of allergen-induced circulating eosinophils and their progenitors grown in the presence of GM-CSF, which may partially be a result of regulating eosinophil progenitor expression of the autocrine growth factor GM-CSF.	Budesonide	8-18	colony stimulating factor 2	Homo sapiens	132-138	
11112128-7	2000	Inhaled budesonide attenuated the number of allergen-induced circulating eosinophils and their progenitors grown in the presence of GM-CSF, which may partially be a result of regulating eosinophil progenitor expression of the autocrine growth factor GM-CSF.	Budesonide	8-18	colony stimulating factor 2	Homo sapiens	250-256	
11029322-7	2000	These results show that budesonide inhibits eosinophil activation primarily through effects on lung fibroblasts, presumably by inhibiting production of granulocyte-macrophage colony-stimulating factor.	Budesonide	24-34	colony stimulating factor 2	Homo sapiens	152-200	
10433506-0	1999	IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.	Budesonide	25-35	colony stimulating factor 2	Homo sapiens	50-56	
10433506-9	1999	GM-CSF production was totally inhibited by budesonide at 10(-8) M in vehicle treated cultures, while IL-10 was inhibited to 33.4+/-4.3% of control.	Budesonide	43-53	colony stimulating factor 2	Homo sapiens	0-6	
10433506-10	1999	IL-2, IL-4, or IL-2 + IL-4 reduced the inhibitory effects of budesonide on GM-CSF to similar levels (23.7 6.7, 31.6+/-8.5 and 35.1+/-4.3% of control, respectively).	Budesonide	61-71	colony stimulating factor 2	Homo sapiens	75-81	
10433509-6	1999	The topically active steroids fluticasone propionate (EC50= 1.8 x 10(-11) M) and budesonide (EC50=5.0 x 10(-11) M) were more potent in inhibiting GM-CSF release from A549 cells than tipredane (EC50 = 8.3 x 10(-10)) M), butixicort (EC50 = 3.7 x 10(-8) M) and dexamethasone (EC50 = 2.2 x 10(-9) M).	Budesonide	81-91	colony stimulating factor 2	Homo sapiens	146-152	
10718988-6	2000	Preincubation of the cells with different concentrations of budesonide was also effective in down-regulating the C5a-induced ICAM-1 expression on HBECs and the ah-CD23 and GM-CSF-induced LFA-1 and Mac-1 expression on eosinophils.	Budesonide	60-70	colony stimulating factor 2	Homo sapiens	172-178	
11424740-3	1999	We speculated that the relatively small inhibitory effect of budesonide on the survival of NP-EOS could be the result of these EOS being exposed to substantial amounts of GM-CSF, IL-5 or IL-3.	Budesonide	61-71	colony stimulating factor 2	Homo sapiens	171-177	
8003851-9	1994	In contrast, GM-CSF release in these cultures was almost totally inhibited by budesonide (> or = 10(-8) M).	Budesonide	78-88	colony stimulating factor 2	Homo sapiens	13-19	
8003851-10	1994	The IC50 for inhibition of the GM-CSF secretion was as low as 2 x 10(-10) M. In the AM cultures, budesonide had very little effect on IL-1 beta and IL-6 secretion (inhibition to 80% and 60% of control levels, respectively), while GM-CSF secretion was suppressed to 20% of control by budesonide concentrations > or = 10(-7) M.(ABSTRACT TRUNCATED AT 250 WORDS)	Budesonide	97-107	colony stimulating factor 2	Homo sapiens	31-37	
2054193-9	1991	Budesonide inhibited both spontaneous and interleukin-1 (IL-1)-induced GM-CSF production by cultured HBEC.	Budesonide	0-10	colony stimulating factor 2	Homo sapiens	71-77	
2054193-10	1991	In addition, preincubation of eosinophils with budesonide caused marked abrogation of the survival induced subsequently with either HBEC-CM or recombinant human GM-CSF.	Budesonide	47-57	colony stimulating factor 2	Homo sapiens	161-167